Courtney DiNardo, MD,MSCE – Azacitidine,Venetoclax, IDH inhibitor

Courtney D. DiNardo, MD, MSCE Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Courtney DiNardo, MD, from MD Anderson Cancer Center, discussed IDH inhibitor therapy at a recent conference. She emphasized the benefits of combining IDH inhibitors with other treatments, showcasing a promising triplet therapy involving azacitidine, venetoclax, and IDH inhibitor.

Register – AML-ALL US Focus Meeting 2023

aml-allus2023.md-education.com

Courtney D. DiNardo highlighted the conference’s conducive environment for meaningful discussions and valuable exchanges, fostering excitement about future advancements in the field.